Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Total Non-Current Liabilities (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 49.08% to $5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Dec 2025, up 49.08% year-over-year, with the annual reading at $8.4 million for FY2025, N/A changed from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $5.7 million at Neuphoria Therapeutics, down from $6.7 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $8.4 million in Q2 2025, with the low at $3.6 million in Q2 2022.
  • Average Total Non-Current Liabilities over 4 years is $5.3 million, with a median of $5.0 million recorded in 2025.
  • The sharpest move saw Total Non-Current Liabilities rose 5.99% in 2023, then surged 49.08% in 2025.
  • Over 4 years, Total Non-Current Liabilities stood at $3.6 million in 2022, then rose by 5.99% to $3.8 million in 2023, then increased by 0.32% to $3.8 million in 2024, then skyrocketed by 49.08% to $5.7 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $5.7 million, $6.7 million, and $8.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.